SCHEDULE: Harel Insurance Discloses 5.2% Stake in Brainsway Ltd.

Harel Insurance Investments & Financial Services Ltd. has reported a 5.2% beneficial ownership stake in Brainsway Ltd. through a Schedule 13G filing.

Summary

• Harel Insurance Investments & Financial Services Ltd. (the "Reporting Person") filed a Schedule 13G regarding its beneficial ownership in Brainsway Ltd.
• The Reporting Person beneficially owns 1,981,714 Ordinary Shares of Brainsway Ltd.
• This represents 5.2% of Brainsway Ltd.'s outstanding Ordinary Shares.
• The percentage is based on 37,789,726 Ordinary Shares issued and outstanding as of June 30, 2025, as reported by Brainsway Ltd. in a Form 6-K.
• The shares are primarily held for members of the public through various funds (provident, mutual, pension, insurance policies, exchange-traded funds) managed by subsidiaries of the Reporting Person.
• These subsidiaries operate under independent management and make independent voting and investment decisions.
• A smaller portion, 7,242 Ordinary Shares, is held by third-party client accounts managed by a subsidiary, which has no voting power in these specific securities.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of Brainsway Ltd.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor has taken a substantial passive stake, indicating potential long-term confidence in Brainsway Ltd. without any immediate negative implications.

Positives

• A significant institutional investor, Harel Insurance, has taken a substantial passive stake (5.2%) in Brainsway Ltd., potentially indicating confidence in the company's long-term prospects.
• The investment is primarily held through various managed funds and policies, suggesting a diversified, long-term investment approach rather than a speculative position.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Brainsway Ltd. or Harel Insurance regarding future performance or strategic direction.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can sometimes signal institutional confidence in a company within its sector. While this filing doesn't offer operational details, a 5.2% stake by a major financial services firm like Harel Insurance in a medical device company like Brainsway Ltd. suggests a belief in the long-term value proposition of Brainsway's technology or market position, potentially aligning with broader trends in healthcare technology investment.

Comparison to Industry Standards

• This filing is a standard disclosure for passive institutional investors acquiring more than 5% of a company's shares, aligning with SEC regulations for Schedule 13G filings.
• The beneficial ownership structure, where shares are held through various managed funds with independent decision-making, is typical for large financial institutions like Harel Insurance, similar to how BlackRock or Vanguard manage their diverse portfolios.
• The certification that the investment is not for control purposes is standard for a 13G filing, differentiating it from a 13D filing which would indicate an intent to influence or control the issuer.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially enhancing liquidity and stability.
• Management: No direct impact on management or operations, as the filing explicitly states no intent to influence control.

Next Steps

• Harel Insurance will continue to monitor its investment in Brainsway Ltd.
• Brainsway Ltd. will continue its regular SEC reporting.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Harel Insurance, has acquired a 5.2% passive stake in Brainsway Ltd. This suggests a vote of confidence from a major financial entity, which is generally a positive indicator. However, as a Schedule 13G, it explicitly states no intent to influence control, meaning it's a passive investment. Without additional operational or financial performance data from Brainsway Ltd., a 'hold' recommendation is appropriate. The institutional interest provides a floor, but there's no new information to warrant a 'buy' or 'sell' based solely on this ownership disclosure.

Keywords

Brainsway Ltd., Harel Insurance, Schedule 13G, Beneficial Ownership, ADS, Ordinary Shares, Institutional Investment, SEC Filing, 10501L106